Drugs in R & D

, Volume 2, Issue 1, pp 38–39 | Cite as

TBC 11251

IPI 1040
Adis R&D Profile


Chronic Obstructive Pulmonary Disease Congestive Heart Failure Adis International Limited Pulmonary Hypertension Pulmonary Artery Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-Aselective antagonist. J Med Chem 1997 May 23; 40: 1690–7PubMedCrossRefGoogle Scholar
  2. 2.
    Texas biotechnology completes phase I safety trial for oral endothelin antagonist. PR Newswire [online].: Available from: URL: [Accessed 1997 Dec 12]
  3. 3.
    Texas Biotechnology Corporation. Texas Biotechnology presents clinical results on its endothelin A receptor antagonist, TBC11251, at AHA sessions [media release]. 1998 Nov 10Google Scholar
  4. 4.
    Givertz M, Colucci WS, Gottlieb SS, et al. Acute ET(A) receptor blockade reduces pulmonary vascular resistance in patients with chronic heart failure. Circulation 1998 Oct 27; 98 Suppl.: 578Google Scholar

Copyright information

© Adis International Limited. 1999

Personalised recommendations